These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 17461771)

  • 1. The peptide nucleic acid targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma lacks immunogenicity: follow-up characterization of PNAEmu-NLS.
    Cutrona G; Boffa LC; Mariani MR; Matis S; Damonte G; Millo E; Roncella S; Ferrarini M
    Oligonucleotides; 2007; 17(1):146-50. PubMed ID: 17461771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of mutagenicity and clastogenicity of PNAEmu-NLS targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma.
    Boffa LC; Menichini P; Bolognesi C; Cutrona G; Roncella S; Damonte GL; Millo E; Mariani MR; Matis S; Russo D; Ciliutti P; Ferrarini M
    Mutat Res; 2007 Apr; 628(2):129-37. PubMed ID: 17267263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma.
    Boffa LC; Cutrona G; Cilli M; Mariani MR; Matis S; Pastorino M; Damonte G; Millo E; Roncella S; Ferrarini M
    Oligonucleotides; 2005; 15(2):85-93. PubMed ID: 15989423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PNAEmu can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease.
    Matis S; Mariani MR; Cutrona G; Cilli M; Piccardi F; Daga A; Damonte G; Millo E; Moroni M; Roncella S; Fedeli F; Boffa LC; Ferrarini M
    Cancer Gene Ther; 2009 Oct; 16(10):786-93. PubMed ID: 19363465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc.
    Boffa LC; Cutrona G; Cilli M; Matis S; Damonte G; Mariani MR; Millo E; Moroni M; Roncella S; Fedeli F; Ferrarini M
    Cancer Gene Ther; 2007 Feb; 14(2):220-6. PubMed ID: 17053816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
    Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
    Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
    Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
    Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells.
    Polack A; Feederle R; Klobeck G; Hörtnagel K
    EMBO J; 1993 Oct; 12(10):3913-20. PubMed ID: 8404859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
    Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
    Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
    Bemark M; Neuberger MS
    Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal.
    Cutrona G; Carpaneto EM; Ulivi M; Roncella S; Landt O; Ferrarini M; Boffa LC
    Nat Biotechnol; 2000 Mar; 18(3):300-3. PubMed ID: 10700145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topological organization of the MYC/IGK locus in Burkitt's lymphoma cells assessed by nuclear halo preparations.
    Rätsch A; Joos S; Kioschis P; Lichter P
    Exp Cell Res; 2002 Feb; 273(1):12-20. PubMed ID: 11795942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
    Habel ME; Lemieux R; Jung D
    J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of immunoglobulin kappa elements in c-myc activation.
    Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
    Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
    Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
    EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
    Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
    Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
    Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
    Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
    Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
    Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
    Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.